OR WAIT 15 SECS
© 2020 MJH Life Sciences and Pharmaceutical Executive. All rights reserved.
© 2020 MJH Life Sciences™ and Pharmaceutical Executive. All rights reserved.
July 01, 2011
Pedal to the Mettle
Structuring a good deal depends on understanding your partner-and a high degree of specificity
What India's latest census tells us about current and future pharma opportunities.
While Europe's EFPIA preaches about embracing change, much remains to be done to prove the adjustment in philosophy
EAB Member Al Topin delivers 10 questions that should drive your brand-building marketing program.
If you can learn to understand patient and physician behavior, you are well on your way to strengthening the position of your product
A country that bridges East and West, old and new-while boasting a growing economy in Europe-is being looked to for its pool of talented industry resources
Sponsors must handle interchangeability, exclusivity, cost and coverage hurdles to win biosimilars game
Pfizer's crizotinib development program combined organization, art, and science-and a large dose of unforeseen risk
More bad ideas on how to manage the healthcare burden are circulating beyond the stakeholders that initiated them
The objective is to make most cancers a curable, chronic condition. But with soaring costs, crowded therapeutic competition, and new diagnostic reimbursement challenges ahead, can industry deliver?
'Like' and 'Dislike' practices in the virtual Facebook pharmaceutical world.
Taking Onyx Pharmaceuticals to new heights – CEO Tony Coles talks to PharmExec about the midsize company's transition from adolescence to adulthood.